Clinical Trial Update: Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab plus fulvestrant in hormone receptor-positive, HER-2-negative advanced/metastatic breast cancer; the trial status is acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Nancy Chan, MD | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING